Phaseline

Companies › Aveta Biomics

Aveta Biomics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
APG-157–Phase 2Head and Neck Cancer; Glioma; Oropharyngeal DysplasiaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05312710APG-157Phase 2Head and Neck CancerOncologyDec 2026
NCT06011109APG-157Phase 1GliomaOncologyDec 2026
NCT05865028APG-157Phase 2Oropharyngeal DysplasiaOncologyMay 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.